Mark Niosi

1.4k total citations
22 papers, 542 citations indexed

About

Mark Niosi is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Mark Niosi has authored 22 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pharmacology and 11 papers in Molecular Biology. Recurrent topics in Mark Niosi's work include Drug Transport and Resistance Mechanisms (13 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Mark Niosi is often cited by papers focused on Drug Transport and Resistance Mechanisms (13 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Mark Niosi collaborates with scholars based in United States, United Kingdom and Canada. Mark Niosi's co-authors include Jian Lin, Li Di, Keith Riccardi, Manthena V. S. Varma, Cheng Chang, Phillip D. Yates, Theunis C. Goosen, Rachel E. Kosa, Michelle Pearson and Gary Lee and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and European Journal of Pharmacology.

In The Last Decade

Mark Niosi

21 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Niosi United States	13	238	209	172	97	56	22	542
Daniel C. Kemp United States	9	124 0.5×	133 0.6×	179 1.0×	56 0.6×	20 0.4×	11	488
Claire Denizot France	13	309 1.3×	110 0.5×	151 0.9×	159 1.6×	18 0.3×	27	563
Daniel R. Mudra United States	11	200 0.8×	270 1.3×	217 1.3×	49 0.5×	37 0.7×	18	647
Wataru Kishimoto Japan	15	449 1.9×	431 2.1×	224 1.3×	197 2.0×	30 0.5×	29	953
Iain Martin United Kingdom	16	147 0.6×	138 0.7×	235 1.4×	40 0.4×	72 1.3×	26	651
Stella Vincent United States	16	182 0.8×	145 0.7×	285 1.7×	55 0.6×	34 0.6×	35	712
Atsushi Ose Japan	10	346 1.5×	129 0.6×	128 0.7×	182 1.9×	41 0.7×	18	601
Kazutomi Kusano Japan	20	241 1.0×	269 1.3×	310 1.8×	127 1.3×	36 0.6×	46	902
Masanori Nakakariya Japan	12	271 1.1×	132 0.6×	214 1.2×	138 1.4×	35 0.6×	27	627
Huan‐Chieh Chien United States	16	303 1.3×	72 0.3×	391 2.3×	118 1.2×	28 0.5×	22	809

Countries citing papers authored by Mark Niosi

Since Specialization

Citations

This map shows the geographic impact of Mark Niosi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Niosi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Niosi more than expected).

Fields of papers citing papers by Mark Niosi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Niosi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Niosi. The network helps show where Mark Niosi may publish in the future.

Co-authorship network of co-authors of Mark Niosi

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Niosi. A scholar is included among the top collaborators of Mark Niosi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Niosi. Mark Niosi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Niosi, Mark, Sam Zhang, Woodrow Burchett, et al.. (2025). Applications of contemporary tools to measure plasma protein binding of targeted protein degraders. Drug Metabolism and Disposition. 53(5). 100066–100066.

Dowty, Martin E., Ruolun Qiu, Alyssa Dantonio, et al.. (2024). The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite. Drug Metabolism and Disposition. 52(7). 690–702. 4 indexed citations

Lapham, Kimberly, et al.. (2024). Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2′-O-Glucuronide Formation as a Selective UGT2B4 Probe Reaction. Drug Metabolism and Disposition. 52(10). 1083–1093. 3 indexed citations

Rodrigues, David, Mark Niosi, Heather Eng, et al.. (2023). Attempting to Unmask the Inhibition of Sulfotransferase 1E1 in 17α‐Ethinyl Estradiol Drug Interactions. The Journal of Clinical Pharmacology. 63(8). 875–879. 2 indexed citations

Lapham, Kimberly, Ernesto Callegari, Julie Cianfrogna, et al.. (2020). In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes. Drug Metabolism and Disposition. 48(12). 1350–1363. 16 indexed citations

Lapham, Kimberly, Jian Lin, Jonathan J. Novak, et al.. (2018). 6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol. Drug Metabolism and Disposition. 46(12). 1836–1846. 5 indexed citations

Kimoto, Emi, Sumathy Mathialagan, Laurie Tylaska, et al.. (2018). Organic Anion Transporter 2–Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability–Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. Journal of Pharmacology and Experimental Therapeutics. 367(2). 322–334. 46 indexed citations

Bruyn, Tom De, Carina Cantrill, Rachel E. Kosa, et al.. (2018). Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance. Drug Metabolism and Disposition. 46(7). 989–1000. 40 indexed citations

Li, Rui, Mark Niosi, Nathaniel Johnson, et al.. (2018). A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects. Drug Metabolism and Disposition. 46(4). 346–356. 18 indexed citations

10.

Achour, Brahim, Alyssa Dantonio, Mark Niosi, et al.. (2018). Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5′-Diphosphate–Glucuronosyltransferase Enzymes with Reference to Catalytic Activity. Drug Metabolism and Disposition. 46(6). 805–812. 21 indexed citations

11.

Li, Rui, Emi Kimoto, Mark Niosi, et al.. (2018). A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects. Drug Metabolism and Disposition. 46(4). 357–366. 7 indexed citations

12.

King‐Ahmad, Amanda, Amit S. Kalgutkar, Mark Niosi, Heather Eng, & Christopher L. Holliman. (2018). A Sensitive Method for the Quantitation of the Peptide-Based Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Plasma Using Microfluidics Chromatography Tandem MS. Bioanalysis. 10(5). 357–368. 5 indexed citations

13.

Riccardi, Keith, Jian Lin, Mark Niosi, et al.. (2017). Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes. Drug Metabolism and Disposition. 45(5). 576–580. 42 indexed citations

14.

Thakare, Rhishikesh, Hongying Gao, Rachel E. Kosa, et al.. (2017). Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. Drug Metabolism and Disposition. 45(7). 721–733. 38 indexed citations

15.

Achour, Brahim, Alyssa Dantonio, Mark Niosi, et al.. (2017). Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity. Drug Metabolism and Disposition. 45(10). 1102–1112. 36 indexed citations

16.

Riccardi, Keith, Zhongrui Li, Janice A. Brown, et al.. (2016). Determination of Unbound Partition Coefficient and in Vitro–in Vivo Extrapolation for SLC13A Transporter–Mediated Uptake. Drug Metabolism and Disposition. 44(10). 1633–1642. 23 indexed citations

17.

Riccardi, Keith, Phillip D. Yates, Cheng Chang, et al.. (2015). Plasma Protein Binding of Challenging Compounds. Journal of Pharmaceutical Sciences. 104(8). 2627–2636. 86 indexed citations

18.

Dow, Robert L., Jiancheng Li, E. Michael Gibbs, et al.. (2013). Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor. Bioorganic & Medicinal Chemistry. 21(17). 5081–5097. 17 indexed citations

19.

Eng, Heather, Mark Niosi, Thomas S. McDonald, et al.. (2010). Utility of the carboxylesterase inhibitorbis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor. Xenobiotica. 40(6). 369–380. 53 indexed citations

20.

Wu, Gang, Garth T. Whiteside, Gary Lee, et al.. (2004). A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats. European Journal of Pharmacology. 504(1-2). 45–53. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact